Skip to content
logo with text
  • What we do
    • Scouting and Out-Licensing
    • Consulting to BD&L
    • Training
  • Current Projects
    • Topical Candidate for Eczema and Related Conditions
    • Custom Nanocomplex Formulation Opportunities
  • About Us
  • Contact
Menu
  • What we do
    • Scouting and Out-Licensing
    • Consulting to BD&L
    • Training
  • Current Projects
    • Topical Candidate for Eczema and Related Conditions
    • Custom Nanocomplex Formulation Opportunities
  • About Us
  • Contact
Read more about the article Grounded in Swords: Comments in the Aftermath of BEU25

Grounded in Swords: Comments in the Aftermath of BEU25

  • Post author:Carlos
  • Post published:November 12, 2025
  • Post category:Artificial Intelligence/Business Development/Licensing/China/Conferences/Venture Capital
  • Post comments:0 Comments

Finding myself with a lengthy layover at the Dublin Airport in Swords, Ireland, on my way to New York from BIO-Europe (and with a surprising lack of Guinness at the…

Continue ReadingGrounded in Swords: Comments in the Aftermath of BEU25
Read more about the article #BIO2025: Five Themes

#BIO2025: Five Themes

  • Post author:Carlos
  • Post published:June 30, 2025
  • Post category:Business Development/Licensing/Conferences/Financing
  • Post comments:0 Comments

Introduction One of the benefits of having BIO in Boston is that it provides me with a ~3.5 hour drive back to New York. This gives me a chance to…

Continue Reading#BIO2025: Five Themes

Year in Review Video – 2024 Edition

  • Post author:Carlos
  • Post published:December 12, 2024
  • Post category:Conferences/Financing/Government/Venture Capital
  • Post comments:0 Comments

https://youtu.be/ryfz4zM6RJA Our Annual Year in Review Video - 2024 Edition At long last, here is our Annual Year in Review video - 2024 Edition.  In this video, we cover: FDA…

Continue ReadingYear in Review Video – 2024 Edition
Read more about the article Partnering in 2022: What’s New?

Partnering in 2022: What’s New?

  • Post author:Carlos
  • Post published:June 10, 2022
  • Post category:Business Development/Licensing/Conferences
  • Post comments:0 Comments

Still working on that wave? Like many of you, I am also knee-deep in last minute preparations for BIO. For many of us, this will be the first live partnering…

Continue ReadingPartnering in 2022: What’s New?
Read more about the article The Future of Partnering Conferences

The Future of Partnering Conferences

  • Post author:Carlos
  • Post published:June 30, 2021
  • Post category:Conferences/COVID-19
  • Post comments:3 Comments

Sign of the times... Passport in date? Check Suits still fit? Too big, but wearable. Negative COVID tests? Yes! Three in hand. Fully Vaccinated? Yes, since April. Masks? Plenty. But…

Continue ReadingThe Future of Partnering Conferences
Read more about the article Clusters Revisited

Clusters Revisited

  • Post author:Carlos
  • Post published:February 5, 2021
  • Post category:Business Development/Licensing/Conferences/Government
  • Post comments:0 Comments

…the enduring competitive advantages in a global economy lie increasingly in local things – knowledge, relationships, motivation – that distant rivals cannot match.  When Michael Porter wrote this in 1998,…

Continue ReadingClusters Revisited
Read more about the article Virtual Partnering Survey Results

Virtual Partnering Survey Results

  • Post author:Carlos
  • Post published:May 11, 2020
  • Post category:Conferences
  • Post comments:0 Comments

Many thanks to every one who participated in our recent survey on virtual / digital partnering.  On the day this survey launched, the US had ~394,000 cases of COVID-19, with…

Continue ReadingVirtual Partnering Survey Results
Read more about the article A Post-COVID-19 World

A Post-COVID-19 World

  • Post author:Carlos
  • Post published:April 13, 2020
  • Post category:Conferences/Drug Development/Due Diligence/Pharmaceutical
  • Post comments:0 Comments

What will our industry and economy look like in the post-COVID-19 era?First of all, we would never recommend paying too much attention to anyone who knows precisely what the answer…

Continue ReadingA Post-COVID-19 World
Read more about the article The Show Must Go On

The Show Must Go On

  • Post author:Carlos
  • Post published:April 2, 2020
  • Post category:Business Development/Licensing/Conferences
  • Post comments:0 Comments

Empty spaces. What are we living for? Abandoned places. I guess we know the score... Over the past few months, our industry has been thrust in a variety of different…

Continue ReadingThe Show Must Go On

Virtual Partnering Survey

  • Post author:Carlos
  • Post published:March 9, 2020
  • Post category:Conferences
  • Post comments:0 Comments

Are virtual or digital partnering conferences the wave of the future? Or will we revert back to face to face conferences once the current crisis is over?We are conducting a…

Continue ReadingVirtual Partnering Survey
  • 1
  • 2
  • 3
  • 4
  • …
  • 8
  • Go to the next page

Recent Posts

  • GIGO: AI and Drug Candidate Valuation – Part V
  • The Platform Question: AI and Drug Candidate Valuation – Part IV
  • On Getting pAId: AI and Drug Candidate Valuation – Part III
  • Children And Crayons: AI and Drug Candidate Valuation – Part II
  • Clowns on a Stage

Archives

  • March 2026
  • February 2026
  • January 2026
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • June 2025
  • December 2024
  • October 2024
  • September 2024
  • April 2024
  • May 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • June 2022
  • March 2022
  • June 2021
  • February 2021
  • December 2020
  • September 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • July 2019
  • June 2019
  • May 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • May 2014
  • April 2014
  • February 2014
  • January 2014
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010

Categories

  • Artificial Intelligence
  • BD&L
  • Biosimilars
  • Biotech
  • Business Development/Licensing
  • China
  • Conferences
  • COVID-19
  • CRO
  • Diagnostics
  • Digital Health
  • Digital Medicine
  • Downsizing
  • Drug Delivery
  • Drug Development
  • Drug Discovery
  • Due Diligence
  • Emerging Markets
  • Entrepreneurship
  • Europe
  • Financing
  • Generics
  • Government
  • India
  • Marketing
  • Mergers & Acquisitions
  • Offshoring
  • Outsourcing
  • Pharmaceutical
  • Planning
  • Pricing
  • Reimbursement
  • Social Media
  • Tech Transfer
  • Uncategorized
  • Venture Capital

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

Get in touch

To contact us, please email us at mail: info@lacertabio.com to schedule your free consultation, or call tele:+1 (845) 293-3343.